. 2011 Jun 7;35(1):9–18. doi: 10.1007/s13402-011-0052-6

Table 6.

Studies reporting FR-α expression in ovarian cancer

Study	No. of patients	Method	FR-α expression
Toffoli (1997)[17]	136	Cytofluorimetric	89.7%
Wu (1999)[19]	23	In situ hybridization histochemistry	100% serous (n = 10);
			80% endometrioid (n = 5);
			0% mucinous (n = 6);
			0% clear-cell (n = 2)
Bagnoli (2003)[3]	168	Immunohistochemistry	85.1% non-mucinous^a
Parker (2005)[14]	29	Radioligand binding assay	100% serous (n = 7);
			100% endometrioid (n = 4);
			36% mucinous (n = 14)^b;
			100% metastatic (n = 4)
Kalli (2008)[8]	186	Immunohistochemistry	81.7% serous (n = 104);
			66.7% endometrioid (n = 39);
			22.2% mucinous (n = 9);
			63.3% clear-cell (n = 30);
			50% mixed (n = 4)
Markert (2008)[12]	104	Immunohistochemistry	97% non-mucinous^c

^aSerous, endometrioid and clear-cell carcinoma

^bOf 14 mucinous tumors, 36% showed only weak FR-α expression

^cSerous (n = 8), serous-papillary (n = 79) and papillary carcinoma (n = 17)